China Biopharmaceutical and Pharmaceutical Regulatory Framework Reforms
By CPhI ChinaThe China Food and Drug Administration has noted a number of reforms to biopharmaceutical and pharmaceutical policy frameworks, aiming to encourage development, approval, and manufacture of required therapies.
Shanghai-based legal experts Katherine Wang and Xiaoyi Liu of Ropes & Gray explain key elements of these new regulations and implications on Western companies.
Download this free whitepaper to find an overview of the Chinese Food and Drug Administrations's new programmes, answering questions such as what opportunities will be presented to Western contract manufacturers, what does the new classification system for new drugs mean for Western companies wishing to introduce new drugs to the Chinese market, and what opportunities are available for Western companies under the fast-track approval pathway?
